New hope for EoE patients? drug trial targets those failed by steroids

NCT ID NCT07588568

Not yet recruiting Disease control Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether upadacitinib, a drug already used for other conditions, can help adults with eosinophilic esophagitis (EoE) who still have symptoms despite using topical steroids. Over 12 weeks, 52 participants will take either upadacitinib or a placebo, then all will receive upadacitinib for another 12 weeks. The main goal is to see if the drug reduces inflammation in the esophagus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: upadacitinib (RINVOQ)
What this could lead to: If it works, this could offer a new treatment option for people with eosinophilic esophagitis who don't get better with current steroid therapy.
What could go wrong: This is a small, early-phase trial with only 52 participants. It may not show a clear benefit, and upadacitinib has known side effects like infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EOE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eosinophilic esophagitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EOE EOSINOPHILIC ESOPHAGITIS EOSINOPHILIC ESOPHAGITIS (EOE)

Contacts and locations

Locations

Duke University

Durham, North Carolina, 27710, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.